Project Details
Description
A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1- year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase: The ACTION Study
| Status | Active |
|---|---|
| Effective start/end date | 12/20/21 → 12/31/26 |
Funding
- CENTESSA BIOSCIENCES, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.